Advances in medical imaging applied to bone metastases by González Sistal, Ángel et al.
16 
Advances in Medical Imaging  
Applied to Bone Metastases 
Àngel González-Sistal1, Alicia Baltasar Sánchez1,  
Michel Herranz Carnero2 and Álvaro Ruibal Morell2 
1Medical Imaging Research Laboratory, Dpt. Physiological Sciences II 
Faculty of Medicine, University of Barcelona 
2Nuclear Medicine Service, Complexo Hosp. Universitario Santiago de Compostela 
Molecular Imaging Group, IDIS 
Spain 
1. Introduction  
Bone metastases are the result of a primary cancer invasion which spreads into the bone 
marrow through the lymphogenous or hematogenous pathways. Bone metastases are a 
common complication of cancer.The primary cancers that most frequently metastasize to 
bone are breast and prostate cancer (65 - 75 %) amongst many others (thyroid 42 %, lung 36 
% or kidney 35 %) (Suva et al., 2011). Although the exact incidence of bone metastases is 
unknown given its dependence on the type of primary cancer, it is estimated that 350,000 
people die of bone metastases annually in the United States. 
1.1 Bone structure and microenvironment 
Bone is the third most common site of hematogenous tumor metastases after liver and 
lungs. The imbalance in bone turnover results in a favorable environment for the growth of 
metastatic tumors, a process known as the vicious cycle of bone metastases (Fili et al., 2009).  
Bone consists of cortical, trabecular and marrow components. Cortical bone, is compact 
and has canals containing vessels. A layer of compact bone surrounds trabecular bone, 
which contains the bone marrow. Most of the red marrow (hematopoietic) is located in 
axial bones (spine, ribs, pelvis, proximal femora), whereas fat marrow is found in 
appendicular bones (long bones). Bone tissue contain the cells types: osteoblasts, 
osteoclasts, osteocytes and bone-lining cells. 
Breast and prostate carcinomas have a great avidity for bone because the molecular 
interactions between these cancer cells and host cells favor the establishment of osseous 
lesions. Thyroid, lung, kidney, gastric, colon and skin cancers also metastasize usually to 
bone but, to a lesser degree, because these cell types do not possess the properties needed 
for invasion and residence in the bone microenvironment (Weilbaecher et al., 2011). 
A number of factors contribute to the high incidence of bone metastases (Eriksen, 2010): 
high blood flow in the red marrow; adhesive molecules on tumor cells that bind them to 
marrow stromal cells and bone matrix (tumor cells increase the production of angiogenic 
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and bone-resorbing factors that further enhance tumor growth in bone); growth factors 
(transforming growth factor b (TGF b), insulin-like growth factors I and II (IL-I and IL-II), 
fibroblast growth factors (FBG), platelet-derived growth factors and bone morphogenetic 
proteins (BMPs)) that are released and activated during bone resorption, providing fertile 
ground in which tumor cells can grow (Suva et al., 2009). 
The adult skeleton continually turns over and remodels itself. There is a balanced 
remodeling sequence: osteoclasts resorb bone on trabecular surfaces and then osteoblasts 
form bone at the same site (Hadjidakis et al., 2006). 
1.2 Types and localization of bone metastases 
Most tumor implants occur through the hematogenous pathway. The preference for axial 
involvement is also due to the greater vascularity of the red marrow found in the axial 
skeleton as opposed to the yellow marrow (high-fat) found in the appendicular bone. Bone 
metastases are characterized as “lytic”(bone destructive), “blastic / sclerotic” (bone forming) 
or “mixed” according to the radiographic and/or pathologic appearance of the lesion. This 
classification represents the dysregulation of the normal bone remodeling process mediated 
by osteoblasts, osteoclasts and tumor cells.  
Patients with breast cancer have predominantly osteolytic lesions (Trinkaus et al., 2009), 
although 15 to 20 percent of them have osteoblastic lesions. Bone metastases from kidney, 
lung or thyroid cancers more often are osteolytic. In addition, secondary formation of bone 
occurs in response to bone destruction. Only in multiple myeloma do purely lytic bone 
lesions develop. In contrast, the lesions in prostate cancer are predominantly osteoblastic. 
(Logothetis & Lin, 2005; Ye et al., 2007). 
1.3 Clinical features 
Bone metastases represent a major cause of morbidity and mortality, once tumors metastasize 
to bone they are usually incurable (Coleman et al., 2011). Bone metastases are rarely silent. 
They can give rise to a number of life-threatening complications (Coleman et al., 2006). 
Osteolytic metastases can cause severe pain, pathologic fractures, decreased mobility, 
hypercalcemia, anemia, spinal cord compression and other nerve-compression syndromes. 
Patients with osteoblastic metastases have bone pain and pathologic fractures because of the 
poor quality of the bone produced by the osteoblasts. Patients with fewer metastases or 
solitary lesions appear to have a better prognosis than those with multiple metastatic deposits. 
1.4 Biomarkers of bone turnover 
Biochemical markers of bone turnover have been used to assess the response to therapy or 
for the detection of bone metastases. Levels of bone-specific alkaline phosphatase, 
osteocalcin and type I procollagen C-propeptide are serum markers of osteoblast activity. 
Whereas, serum levels of C-terminal telopeptide of type I collagen or tartrate-resistant acid 
phosphatase and urinay levels of type I collagen cross-linked N-telopeptides are indicators 
of osteoclast activity (Roodman, 2004).  
There are limitations to the clinical utility of many of these bone markers. Recently, some 
new markers have been described as potentially important role: CXXL16/CXCR6 (Ha et al., 
2011), OPG/RANKL (Mercatali et al., 2011) or CCN3 (Ouellet et al., 2011). 
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2. Pre-clinical cancer research optical imaging modalities 
Optical imaging is based on the detection of photons emitted from living cells, tissues or 
animals. It can be divided into bioluminescence imaging (BLI) and fluorescence imaging 
(FLI). The role of molecular imaging in pre-clinical research is evolving. In small animal 
models optical imaging technologies are used to visualize normal as well as aberrant 
cellular processes at a molecular-genetic or cellular level of function (Chaudhari et al., 2005; 
Kwon et al., 2010; Snoeks et al., 2011). 
The mechanism for creating luminescent light is that luciferase, which acts as a catalyst in 
the presence of oxygen and ATP, converts chemical luciferin into oxyluciferin, releasing 
light in the process. The substrate D-luciferin is injected, distributes rapidly throughout the 
body of the animal and is taken up by the cells. The emitted light is detected by a cooled 
charged coupled device camera (CCD) and has a wavelength from 500 to 620 nm which is 
sufficient to penetrate small animal tissue (Ntziachristos et al., 2005). 
As regards FLI, fluorescence occurs when the excited state is caused by external stimulation 
by light (Leblond et al., 2010). As for BLI, luminescence is caused by a chemical reaction 
(either a natural, biological one- bioluminescence, or a purely chemistry based once 
chemiluminescence) (Kim et al., 2010). Despite its distinctive features each modality 
revealed differences in sensitivity, signal-to-noise-ratio (SNR) and background emission 
from tissues. Autofluorescence of tissue reduces the signal-to-noise ratio, so in fluorescence 
imaging the SNR is expected to be greater than in bioluminescence imaging. 
In vivo expression of reporter genes encoding bioluminescent or fluorescent proteins can be 
detected externally by sensitive detection systems. BLI could easily image in vivo a bone 
metastatic lesion that in the end-point histological analysis results in a tumor of ≈ 0.5 mm3 
volume, corresponding to ≈1.7x104 cells. 
Optical imaging only provides semi-quantitative data because of tissue-dependent signal 
attenuation and poor positional information due to photon scattering. However, new 
advances have made it possible to extend BLI and FLI to 3D imaging by optical 
tomography, ensuring better quantification of photon emission. As a result of the 
development of fluorescence molecular tomography (FMT) and other 3D fluorescence and 
bioluminescence data capturing methods, it is now possible to acquire 3D optical data and 
use different modalities (radiography, μCT, PET, SPECT or MRI) to ensure spatial resolution 
and anatomical detail (Nahrendorf et al., 2010). 
The main advantage of optical imaging is by a noninvasive study its ability to visualize 
biological processes, such as angiogenesis, inflammation or matrix degradation in the 
development and growth of bone metastases (Snoeks et al., 2011). 
3. Diagnosis imaging modalities: Algorithm choice 
Imaging plays a major role given that early identification of skeletal metastases could lead to 
changes in patient management and quality of life. Imaging modalities are based on either 
direct anatomic visualization of the bone or tumor or indirect measurements of bone tumor 
metabolism (figure 1). Clinical evaluation demands multimodal diagnostic imaging owing 
to the limitations of the diagnostic techniques. Four main modalities are currently used in 
clinical practice: radiography, computed tomography (CT), scintigraphy and magnetic 
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resonance imaging (MRI). At present, positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) have a potential for evaluation (Rybak et 
al., 2001; Costelloe et al., 2009).  
These techniques differ in performance in terms of sensitivity and specificity, but none of 
the modalities alone seem to be able to yield a reliable diagnostic outcome. There is 
currently no consensus about the best modality for diagnosing the bone metastases and for 
assessing their response to treatment. In clinical practice, most oncologists do not even use 
the same criteria, which results in disparate assessments of bone metastases (González-
Sistal, 2007; Welch & Black, 2010). 
Although bone metastases can be treated, their response to treatment is considered 
“unmeasurable”, which excludes patients with cancer and bone metastatic disease from 
participating in clinical trials of new treatments (Hamaoka et al, 2010). 
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Fig. 1. Protocol for detection of bone metastases. Each imaging modalities visualize different 
aspects of bone tissue or tumor. (Visualization: 1 bone metabolism, 2 cortical/trabecular bone, 
3 bone marrow / tumor, 4 tumor metabolism; Extension: a local, b regional, c whole body) 
The algorithm of figure 1 shows a classical protocol for detection of bone metastases. The 
proposed algorithm is based in:  
 Scintigraphy remains the technique of choice in asymptomatic patients in whom 
skeletal metastases are suspected (whole-body screening). This technique, albeit very 
sensitive, is poorly specific, and thus a bone scan finding is double-checked with an 
additional examination (radiography, CT or MRI). 
 Radiography is used to evaluate symptomatic sites (bone pain) or confirm findings of 
other imaging modalities 
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 CT and MRI can depict anatomic changes in more detail. CT is preferable for assessing 
axial bone metastases, regardless of whether the main tumor involves the bone marrow 
or cortex. MRI, on the other hand, is better for detecting bone marrow disease or spinal 
cord compression. 
 If MRI and CT cannot detect the disease and clinical suspicion of bone metastases 
remains, a PET/CT is made 
 SPECT is not typically used for the initial detection of metastatic disease. SPECT-CT is 
useful for the assessment of lesions that are not determined in scintigraphy 
4. Gamma-ray techniques 
4.1 99mTc-MDP bone scintigraphy  
Bone scintigraphy is a nuclear medicine tomographic imaging technique using gamma rays. 
Technetium-99m bound to methylene diphosphonate (99mTc-MDP) is the most frequent 
radionuclide used in scintigraphy. The patient is injected this radiopharmaceutical and then 
he is scanned with a gamma camera (a device sensitive to the radiation emitted by the 
patient) which it produces a 2D picture. 
99mTc-MDP bone scintigraphy is the method used to screen the whole body for bone 
metastases. It detects increases in osteoblastic activity and the flow of the blood level. It is a 
marker of bone turn-over or bone metabolism (Moore et al., 2007).  
Scintigraphy is indicated for the following procedures: screening or staging in 
asymptomatic patients, evaluation of persistent bone pain with a negative radiography, 
determination of the extent of bone metastases in patients with positive radiography, 
differentiation of metastatic from traumatic fractures and determination of the therapeutic 
response to bone metastases (Hamaoka et al., 2004).  
A classic pattern is the presence of randomly distributed focal lesions throughout the 
skeleton (figure 2) which appear as areas of increased tracer uptake (“hot spots”). Other 
typical patterns in scintigraphy are superscan (diffuse metastatic disease), cold lesions (due 
to complete absence of reactive bone, they are associated with aggressive carcinomas), 
normal scintiscan, flare phenomenon (osteoblastic activity that reflects bone healing after 
chemotherapy but not advancing disease) and hypercaptation in soft-tissue lesions. 
As regards the degree of confidence, scintiscans are non specific for determining the cause 
of increased uptake (lower specificity) since the findings of scintigraphy reflect the 
metabolic reaction of bone. Bone scintiscans have a poor spatial and contrast resolution. 
Many benign processes can produce an isotope uptake that mimics metastases (false-
positive finding) and approximately one third of patients show a solitary area associated 
with a benign process. Thus, biopsy confirmation may also be needed for the final 
diagnosis of suspicious lesions. The differential diagnosis includes metabolic illness, 
osteomalacia, trauma, arthritis, osteomyelitis, infarctions and Paget’s disease. Therefore, 
suspicious lesions or a single “hot spot” should be verified by other imaging modalities 
such as radiography, CT, or MRI.  
Scintigraphy does not detect pure lytic metastases when bone turnover is slow or when the 
site is avascular. The main advantages of scintigraphy are widely available and can screen 
rapid whole-body images at a reasonable cost. 
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When assessing the therapeutic response, scintigraphy should be supplemented by images 
obtained with other modalities to provide a valid baseline for the assessment of bone tumor. 
In addition, it can take six months or longer to detect a response in the scintigraphy because 
of the confounding effect of the flare phenomenon. 
 
Fig. 2. 99mTc bone scintigraphy images of a patient with prostatic carcinoma. This is a classical 
pattern with the presence of randomly distributed focal lesions throughout the skeleton. Bone 
metastases appear as areas of increased tracer uptake (“hot spots”) (red arrows). 
4.2 Single-photon-emission computed tomography (SPECT) 
SPECT is a nuclear medicine tomographic imaging technique using gamma rays. 99mTc-
MDP, the same radionuclide used in conventional skeletal scintigraphy is the most 
frequent radionuclide used. It is very similar to conventional nuclear medicine planar 
imaging using a gamma camera. However, images are acquired in a cross-sectional rather 
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than a planar fashion. It is able to provide 3D information. Compared with a conventional 
scintigraphy, the precise anatomic localisation provided by SPECT ensures a better 
differentiation between benign and malignant diseases. SPECT has greater sensitivity and 
specificity than scintigraphy for detecting vertebral and pelvis metastases (sensitivity 87-
92% and specificity 73-100%). Like scintigraphy, it is possible that SPECT does not detect 
lytic lesions (Beheshti et al., 2009).  
Because of limited availability and poor diagnostic imaging quality, SPECT is not typically 
used for the initial detection of metastatic disease (Chua, 2009). SPECT-CT is useful for the 
assessment of lesions that are not determined in scintigraphy. When scintigraphy are 
reviewed immediately, SPECT or SPECT-CT imaging can be performed in the same session 
without administering a second dose of radionuclide. 
4.3 Positron emission tomography (PET) 
PET is a nuclear medicine imaging technique that produces tomographic images through 
the detection of high-energy photon pairs emitted during positron decay of a radioisotope. 
PET visualizes the uptake of positron-emitting radioisotope by tissues, but, for skeletal 
metastases, two radiopharmaceuticals are typically used: 18F-Fluoride, a bone turnover 
tracer, and 18FDG a tumor tracer. PET can be used for whole-body scanning to detect 
metastases in either soft tissue or bone. PET provides a 3D image of tracer concentration 
within the body that is then constructed by computer analysis. In modern scanners, 3D 
imaging is often accomplished with the CT or MRI on the patient in the same machine. PET 
has a limited spatial resolution and complementary CT scanning or MRI is required to 
localize the specific area (Costelloe et al., 2009; Cook ,2010). 
Its main advantages are: high sensitivity (84-100%), biochemical and molecular information 
(does not always coincide with morphological explorations). PET is an effective technique 
that is used in the evaluation of skeletal metastatic disease, particularly when combined 
with CT, because of its high resolution and coverage of the whole body (Ben-Haim, 2009 & 
Israel, 2009). PET has the advantage of permitting quantification of therapeutic response 
using the maximum standard uptake (mSUV) value. PET can be a sensitive modality for 
diagnosing and monitoring osteolytic response (Beheshti et. al, 2009; Wahl et al., 2009). 
However, the disadvantages may include PET cyclotron or the generator method, its high 
radiation, its high cost, its limited availability, and the additional time required for scanning 
with respect to other imaging modalities. 
4.4 18FDG-PET 
18FDG (2-deoxy-2-[18F]-fluoro-D-glucose or fluorodeoxyglucose) has been used to measure 
glucose metabolism in many types of primary cancer and can be useful for distinguishing 
benign from malignant bone lesions. It is an analog of glucose and represents the most 
widely used PET radiotracer in daily practice. The mechanism of uptake in tumor cells 
consist in the diffusion facilitated by glucose transporters (GLUTs), phosphorylation by 
hexokinase and subsequent metabolic trapping within the cell. It is a reflection of glucose 
metabolism consumption or tissue level. 
Although it is a very sensitive marker, it is not very specific, since increases in tissue uptake 
of 18FDG is not always synonymous with cancer. The main clinical application of this 
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technique consists in diagnosing, staging and restaging of various cancer types (figure 3). It 
is very effective in detecting metastases of breast, lung, esophagus, colon, thyroid, head, 
neck, melanoma and lymphoma. 
From the dosimetric point of view, it should be noted that an administration of 350 MBq of 
18FDG results in a radiation exposure of approximately 6,3-7 mSV and PET/CT examination 
may result in a radiation exposure of more than 22-23 mSv, near the upper range of the dose 
given for regular diagnostic abdomen CT (3,5-25 mSv). 
 
Fig. 3. PET images in a patient with lung carcinoma. (A) 18FDG PET shows the primary 
tumor (red arrow, 4x4.3cm, mSUV=27) with contralateral clavicle nodal metastases (green 
arrow, 2.7x2.5 cm, mSUV=19.2). (B) Incidental right humerus focal uptake is noted (red 
cross) which is suspicious for bone metastases modifying the initial disease staging from the 
patient to stage IV. 
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4.5 18F-fluoride-PET 
The mechanism of 18F-Fluoride uptake is similar to that of 99mTc-MDP, the tracer used in 
scintigraphy: its accumulation depends on osteoblastic activity and local blood flow. It is an 
indicator of bone turnover, but not of a specific tracer of bone metastases. At present, it is 
the second most commonly used technique in oncology, playing an important role in the 
detection of bone involvement. A number of studies have shown that the diagnostic 
accuracy of 18F-fluoride–PET is better than scintigraphy (95,7% vs 75,4%) for detecting bone 
metastases in lung, prostate, thyroid and breast cancer, especially when using PET/CT 
(Withofs et al., 2011). Moreover, it appears to be more sensitive than SPECT. 
The specificity of 18F-Fluoride when used with PET alone is 62% (Groves et al., 2007), which 
demands a CT, mainly pelvic and lumbar injury, and may also detect extra-osseous 
metastases. An advantage is that it can detect early osteoblastic changes in slow growing 
tumors, where 18FDG has a limited value. 18F-fluoride appears to be equally sensitive to 
osteoblastic and osteolytic metastases and can identify extremely early osteoblastic changes 
in response to metastatic deposits. It also seems to be superior in the detection the low 
avidity of bone tumor metastases for 18FDG as in some thyroid cancers.  
Moreover, quantitative 18F-Fluoride PET can determine kinetics of fluoride incorporation 
into bone as a measure of fluoride transport, bone formation and turnover. Kinetic analysis 
(fluoride transport and flux) may be useful in assessing changes in bone turnover in 
response to therapy, and in bone metastases with values exceeding those of normal bone 
(Doot et al., 2010).  
5. X-ray techniques 
5.1 Radiography 
Radiography is an x-ray imaging technique that produces a 2D picture of human body 
structures superimposed on each other, whose insides absord different amounts of radiation 
depending on the densities of its components. Bone metastases can appear on radiography 
as areas of absent density (osteolytic), as disrupted bone structure or as high density 
(osteoblastic). Radiography is a good method for characterizing bone metastases: osteolytic, 
osteoblastic or mixed. The ocurrence of bone metastases suggests a primary tumor, eg. 
osteolytic metastases are typical in breast and lung carcinomas whereas osteoblastic 
metastases are more common in prostatic carcinoma (Hamaoka et al., 2004). Radiography is 
used to evaluate symptomatic sites (bone pain) or confirm findings of other imaging 
modalities (especially for evaluating suspicious lesions on scintigraphy). Radiography may 
be used to assess the risk of a pathological fracture. False positive diagnosis may result 
because osteolytic metastases can mimic osteoarthritis. Osteoblastic metastases may be 
difficult to distinguish from other sclerotic bone lesions such as tuberous sclerosis. 
The disadvantage is that between 30 and 50% of normal bone mineral content must be lost 
before lytic lesions become apparent on radiography (Wahl et al., 2009). Moreover, lesions in 
trabecular bone are more difficult to detect by radiography than cortical. The main 
advantages of radiography are that it is cost effective and widely available. However, it is 
not recommended for screening because of its limited sensitivity, which depends partly on 
location (Rybal & Rosenthal, 2001).  
 
Medical Imaging 
 
348 
Radiography can detect the response of osteolytic lesions by depicting active bone 
formation (blastic change) or the reappearance and normalization of bone structure. But, 
it may be difficult to differentiate bone metastases from healing or previously 
unidentified sclerotic lesions. In several studies, indicators of response to treatment on 
radiography are correlated with clinical symptoms or other changes better than 
scintigraphy. Nevertheless, changes in radiography are not apparent until three to six 
months after the initiation of treatment (Even-Sapir, 2005). 
5.2 Computed tomography (CT) 
CT consists of a large series of 2D x-ray images taken around a single axis of rotation. The 
computer assisted reconstruction is used to generate 3D pictures. The radiologic appearance 
in the CT bone window setting offers skeletal detail because it can distinguish between 
materials of different densities. It is more sensitive than radiography in the detection of bone 
metastases. CT is useful for evaluating radiography negative areas in symptomatic patients 
or where metastases are suggested clinically. CT is important in the evaluation of focal 
abnormalities observed in bone scintigraphy that cannot be confirmed using radiographs.  
Osteolytic, osteoblastic and mixed bone metastases are well despicted on CT. It can detect 
metastases in the marrow. Bone metastases appear more attenuated than the marrow. But 
the usefulness of CT in detecting early deposits in bone marrow is limited. Although CT is 
superior to radiography some advanced destructive lesions on trabecular bone may not be 
visible in the absence of cortical bone involvement, so CT is less apparent than the marrow 
changes visualized on MRI (Hamaoka et al., 2004). CT is also better than radiography and 
scintigraphy for depicting lesions in the spine and calvarium. CT is useful in guiding needle 
biopsy in bones such as vertebrae or ilia.  
The disadvantage of CT is that its high radiation dose makes CT unsuitable as a screening 
tool. Thus, limited anatomic areas can be scanned simultaneously (Rybal & Rosenthal, 2001). 
When assessing the therapeutic response, sclerosis of a lytic component on CT suggests a 
response to treatment. Notwithstanding, lysis or the appearance of new lysis or an 
increase in the size of blastic lesion represents a disease progression (Hamaoka et al., 2009; 
Wahl et al., 2009).  
5.3 Dual-energy X-ray absorptiometry (DXA) 
DXA is a method for the evaluation of bone mineral density (BMD) and monitoring 
patients with osteopenia or osteoporosis, entailing minimal exposure to radiation (x-ray). 
Two x-ray beams with differing energy levels are aimed at the patient's bones. When soft 
tissue absorption is subtracted out, the BMD can be determined from the absorption of 
each beam by bone.  
BMD reflects the balance between bone formation and resorption. This method has also 
been applied in several clinical trials to assess the therapeutic outcome of patients with bone 
metastases receiving systemic treatments (Vassiliou et al., 2011). The BMD of skeletal 
metastases increases in patients responding to treatment and was significantly correlated 
with the changes imaged on skeletal x-rays and CT. 
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6. Magnetic resonance imaging (MRI) 
MRI produces high quality images of the inside of the human body. It uses a powerful 
magnetic field to align the magnetization of some atoms in the body (hydrogen nuclei or 
protons of the water molecules) and a radiofrequency fields to systematically alter the 
alignment of this magnetization. When a patient is subjected to the powerful magnetic 
field of the scanner, the magnetic moments of some of these protons change and align 
with the direction of the field. An image can be constructed because the protons in 
different tissues return to their state of equilibrium at different rates (tissue variables: spin 
density, T1 and T2 relaxation times, flow and spectral shifts) (Wu, 2011). Unlike the other 
techniques, MRI does not use ionizing radiation.  
MRI diagnosis of bone metastases is characterized by long T1 relaxation times, whereas 
T2 relaxation times are variable, depending on tumor morphology. Metastases are seen as 
focal or diffuse areas of hypointensity on T1-weighted images which contrasts with the 
surrounding high signal marrow fat. Metastases can often be distinguished from focal 
deposits of red marrow because the latter are more focal and may have centrally located 
fat (bull’s eye sign). In the case of T2-weighted images, bone metastases are seen as areas 
of intermediate or high signal intensity which contrast with normal marrow because of 
their high water content, and they are commonly, surrounded by a rim of bright signal 
(halo sign) (Schmidt, 2007).  
MRI can identify bone metastases at an early stage. CT can also visualize bone marrow 
lesions, but the resolution is poor. The advantages of MRI include distinguishing benign 
(osteoporotic) from malignant causes of vertebral compression fracture, detecting spinal 
cord compression and the capability to obtain sagittal views of the entire spine to be 
assessed in one imaging session. Nevertheless, MRI is less advisable than radiography or CT 
for detecting the destruction of cortical bone structure because, cortical appears black on T1 
and T2-weighted sequences.  
Difussion-weighted imaging (DWI) is a MRI technique based on the imaging of molecular 
mobility of water (i.e. diffusion). Recently, DWI has been proposed as a time-and cost-
effective detection to image tumor deposits throughout the whole body. DWI is 
considered a highly sensitive method for the detection of bone metastases (Luboldt, 2008; 
Takenaka, 2009). 
With whole-body MRI, technical problems arise from the relatively long examination times 
(45–60 min) and the limited depiction of metastases in small bones. However, the 
development of ultrafast pulse sequences (Turbo STIR (short tau inversion recovery)) for 
whole-body MRI may substantially decrease imaging time. MRI scanning has 
contraindications, these include: pacemakers, metallic implants or ferromagnetic foreign 
bodies (e. g. shell fragments). Many benign process can produce the appearance of bone 
metastases on MRI ( e.g in vertebral column: degenerative disk disease, osteomyelitis, 
benign compression fracture, infarcts or Schmorl’s nodes). 
When assessing the therapeutic response, MRI is optimal for showing spinal cord status and 
changes in the bone marrow but not suited to showing lytic or blastic change in bone 
structure. 
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7. Imaging modalities in major cancer entities 
7.1 Breast cancer 
The skeleton is the most common site of distant metastases in breast cancer (30%–85%). The 
vertebral column is the most common site of spread followed by the ribs. Bone metastases of 
breast cancer are lytic, blastic or mixed. Scintigraphy is indicated in patients with advanced 
disease or when bone involvement is clinically suspected. The use of 18F-FDG PET it is not a 
routine staging procedure. 18F-FDG PET allows for the detection of both soft-tissue and 
skeletal sites of disease. The superiority of 18F-FDG PET was reflected mainly in the 
detection of bone metastases, which were predominately lytic. By using PET/CT, sclerotic 
lesions overlooked by the PET part of the study can be identified on the CT part. In this 
setting, the high sensitivity of 18F-FDG PET for detecting marrow and lytic lesions and the 
high sensitivity of CT for detecting sclerotic lesions are complementary. Notwithstanding, 
some types of breast cancer, primarily well-differentiated histologic subtypes including 
some of the tubular and lobular ones, are less 18F-FDG avid and so are their metastases. A 
recognized scintigraphy effect of antiestrogen therapy commonly applied in patients with 
breast cancer is the “flare reaction”. Clinically, it may be difficult to differentiate the flare 
reaction from disease progression. The initial agonist effect to therapy is also associated with 
increased tumor 18F-FDG uptake. A change in 18F-FDG uptake can be detected as early as 10 
days after initiation of treatment compared with several weeks that are often required to 
make this assessment on the basis of clinical symptoms (Niikuraet al., 2011).  
7.2 Prostate cancer 
Prostate cancer frequently metastatizes to bone (35-85%). Bone metastases of prostate cancer 
are predominantly blastic. The vertebral column (lumbar), pelvis, sternum, ribs and femur 
are the most common sites of spread. Staging of newly diagnosed prostate cancer is essential 
for guiding treatment. Patients with low-risk prostate cancer are unlikely to have metastatic 
disease on scintigraphy. Patients are referred for scintigraphy mainly if they are considered 
to be at high risk for bone metastases, with high PSA levels, a locally advanced disease, or a 
high Gleason score. Scintigraphy is the most widely used method for evaluating skeletal 
metastases of prostate carcinoma. The role of 18F-FDG PET seemed to be limited in this type 
of cancer as both the soft-tissue sites of disease and bone metastases were reported to be 18F-
FDG negative or to show only a low-intensity uptake in many patients. PET/CT was 
suggested to overcome the problem of pelvic tumor sites being obscured by the radioactive 
urine. Using 18F-FDG PET for monitoring the response to treatment, a decline in tumor 
glucose uptake measured as early as 48 h after androgen withdrawal, preceding any change 
in tumor volume or in PSA levels. Other PET tracers suggested for assessment of prostate 
cancer include 11C- or 18F-labeled choline and acetate, 11C-methionine, 18F-
fluorodihydrotestosterone, and 18F-fluoride. The latter may be highly sensitive for detecting 
bone metastases in patients with prostate cancer (Even-Sapir, 2007). 
7.3 Lung cancer 
Bone metastases are diagnosed at initial presentation in 4%–60% of patients with non-small-
cell lung cancer (NSC). Bone pain is usually considered an indicator of skeletal metastases, 
but up to 40% of lung cancer patients with proven bone metastases are asymptomatic. 
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Surgical resection offers the highest probability of a favorable outcome in patients with NSC 
lung carcinoma. However, the survival of patients who undergo surgery remains low, 
probably because of presurgical understaging. Clinical staging at presentation has been 
performed by means of CT of the thorax through the liver and adrenals, CT or MRI of the 
brain, and scintgraphy for assessment of bone involvement. This staging algorithm remains 
the most commonly used in places where 18F-FDG PET is not a routine staging modality of 
lung cancer. Including SPECT in the acquisition protocol of scintigraphy could improve the 
diagnostic accuracy scintigraphy in detecting bone metastases in patients with lung cancer. 
If necessary, scintigraphy can be complemented by CT or regional MRI for further 
assessment of unclear lesions. 18F-FDG PET and PET/CT were recently reported to be of 
value in assessing the presence of soft-tissue and bone spread in patients with NSC lung 
cancer. They reported that 18F-FDG PET had a high positive predictive value and a lower 
false-positive rate compared with scintigraphy (Even-Sapir, 2007). 
The utility of PET in the detection of bone metastases is demonstrated in the following case 
(figures 4 and 5). A patient with lung carcinoma where the scintigraphy did not detect pure 
lytic metastases caused by slow bone turnover or an avascular site. The PET scan revealed a 
focus of increase FDG uptake suspicious for osteolytic metastases in the spine. MRI was 
requested for confirmation of diagnosis. 
 
Fig. 4. 99mTc-MDP bone scintigraphy images of a patient with lung carcinoma. It is a normal 
scintiscan. The bone scan does not revealed suspicious foci of uptake 
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(A) PET show the primary tumor (red arrow). (B) A subsequent PET scan revealed a focus of increased 
FDG uptake in the spine (L2 vertebral body, red cross) which is suspicious for a osteolytic metastases. 
Fig. 5. PET images in a patient with lung carcinoma. The utility of PET in the detection of 
bone metastases is demonstrated in this case. The bone scan, of the same patient, is showed 
in figure 4: a normal scintiscan (false negative case).  
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